Primary myelofibrosis is a rare blood cancer in which scar tissue gradually replaces the healthy, spongy interior of your bone marrow. Because bone marrow is where blood cells are made, this scarring disrupts normal blood cell production and forces the body to manufacture blood cells in other organs, most commonly the spleen. The result is a cascade of problems: severe fatigue, an enlarged spleen, abnormal blood counts, and a shortened lifespan that varies widely depending on individual risk factors.
How Bone Marrow Becomes Scarred
The scarring process starts with abnormal blood stem cells. In primary myelofibrosis, a genetic mutation causes certain bone marrow cells, particularly the large cells responsible for making platelets (called megakaryocytes), to multiply out of control. These abnormal megakaryocytes release massive amounts of a signaling protein called TGF-beta, at levels 5 to 10 times higher than normal. TGF-beta is the key driver of fibrosis: it stimulates nearby connective tissue cells to produce collagen and other structural fibers that progressively stiffen and scar the marrow.
The process is self-reinforcing. Enzymes that cross-link collagen fibers become overactive in the abnormal megakaryocytes, stabilizing the scar tissue and making it harder for the body to break down. At the same time, the mutant stem cells trigger the growth of bone-forming cells, which further remodel the marrow environment. Over months and years, healthy marrow is replaced by dense, fibrous tissue and sometimes even excess bone.
As the marrow fails, the spleen and liver take over blood cell production, a process called extramedullary hematopoiesis. This compensatory effort causes the spleen to swell dramatically, sometimes filling much of the abdomen.
The Genetic Mutations Behind It
Three driver mutations account for the vast majority of primary myelofibrosis cases, and testing for them is now a standard part of diagnosis. The JAK2 V617F mutation is the most common, found in roughly 50 to 60% of patients. Mutations in the CALR gene account for another 20 to 35%, and mutations in MPL appear in up to 17% of cases. A small percentage of patients have none of these three mutations and are classified as “triple-negative,” which generally carries a worse prognosis.
All three mutations share a common effect: they cause a signaling pathway in blood stem cells to stay permanently switched on, driving uncontrolled cell growth. Identifying which mutation you carry matters because it influences both prognosis and treatment decisions. CALR mutations, for example, tend to be associated with longer survival compared to JAK2 or triple-negative disease.
Symptoms and How They Affect Daily Life
Fatigue is the hallmark symptom, reported by about 85% of patients. This is not ordinary tiredness. It is a deep, persistent exhaustion that doesn’t improve with rest and often limits the ability to work or maintain normal routines. Weight loss, night sweats, and fevers each affect 50% or more of patients. These “constitutional symptoms” reflect the body’s chronic inflammatory state and are significant enough that their presence alone worsens a patient’s prognostic score.
An enlarged spleen creates its own set of problems. Among patients with splenomegaly, 85% report pain or discomfort under the left ribs, 79% experience early satiety (feeling full after eating very little), and 67% have generalized abdominal pain. The swollen spleen physically compresses the stomach, making meals uncomfortable and contributing to the weight loss that many patients experience. Bruising and shortness of breath are also common, affecting roughly 30 to 45% of patients regardless of spleen size.
How It Is Diagnosed
Diagnosis relies on a combination of blood work, bone marrow biopsy, and genetic testing. A blood smear under the microscope reveals characteristic teardrop-shaped red blood cells and a pattern called leukoerythroblastosis, where immature white blood cells and nucleated red blood cells that normally stay in the marrow spill into the bloodstream. These findings reflect the marrow’s inability to function normally.
A bone marrow biopsy confirms the diagnosis by showing increased megakaryocytes alongside collagen fibrosis or, in earlier stages, a hypercellular marrow with abnormal megakaryocyte clustering. The World Health Organization recognizes two stages: a pre-fibrotic stage, where the marrow is packed with cells but not yet heavily scarred, and an overt fibrotic stage, where significant scarring and bone hardening are present. Genetic testing for JAK2, CALR, and MPL mutations rounds out the diagnostic workup.
Estimating Prognosis
Doctors use a scoring system called DIPSS (Dynamic International Prognostic Scoring System) to estimate how aggressive the disease is likely to be. Five factors each contribute a point or more to your score: age over 65, hemoglobin below 10 g/dL (a marker of anemia), white blood cell count above 25,000, circulating immature blast cells at 1% or higher, and the presence of constitutional symptoms like fevers, night sweats, or significant weight loss.
These factors sort patients into four risk categories with strikingly different survival outlooks. Low-risk patients have a median survival of about 10 years. Intermediate-1 patients average around 8 years, while intermediate-2 and high-risk patients historically survived a median of about 2.5 to 4 years. More recent data is encouraging: patients diagnosed in the 2011 to 2020 decade with higher-risk disease saw their median survival improve from roughly 30 months to 45 months, likely reflecting better treatments and earlier intervention.
Treatment With JAK Inhibitors
JAK inhibitor drugs are the primary medical therapy for primary myelofibrosis. These medications work by blocking the overactive JAK signaling pathway that drives the disease. They do not cure myelofibrosis or reverse the marrow scarring, but they can substantially shrink the spleen and relieve constitutional symptoms.
In clinical trials, the first approved JAK inhibitor reduced spleen volume by 35% or more in about 42% of patients at six months. A second JAK inhibitor, tested at its optimal dose, achieved the same spleen reduction threshold in 60% of patients at six months. Symptom scores, including fatigue, night sweats, and abdominal discomfort, also improved in roughly a quarter to a third of treated patients. For many people, this translates into meaningful improvements in quality of life: eating more comfortably, sleeping through the night, and having more energy during the day.
These medications do come with trade-offs. Because they suppress parts of the immune and blood-forming systems, anemia and low platelet counts are common side effects that require monitoring and sometimes dose adjustments.
Stem Cell Transplant as a Cure
The only potentially curative treatment is an allogeneic stem cell transplant, in which a donor’s healthy stem cells replace the patient’s diseased marrow. This is a high-risk procedure with significant complications, including graft-versus-host disease, infections, and transplant-related mortality. Because of these risks, it is generally reserved for patients with intermediate-2 or high-risk disease who are young and fit enough to tolerate the procedure.
Medicare and most insurers require a DIPSS-plus score in the intermediate-2 or high category before approving transplant coverage. Age, overall health, availability of a matched donor, and how long you have had the disease all factor into whether transplant is recommended. For patients who qualify and survive the initial recovery period, long-term remission is possible.
Risk of Transformation to Leukemia
One of the most serious complications of primary myelofibrosis is transformation to acute myeloid leukemia, which occurs in 8 to 23% of patients. This transformation is not necessarily related to prior treatment. It can happen at any point in the disease course but tends to occur later, often as a terminal event. Leukemia arising from myelofibrosis is particularly aggressive and responds poorly to standard chemotherapy, which is one reason doctors monitor blast cell percentages closely during routine blood work. A rising blast count is an early warning sign that the disease may be shifting.